Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
06:14pm, Tuesday, 06'th Jan 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate princ
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript
Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update
02:58pm, Tuesday, 06'th Jan 2026
Arrowhead Pharmaceuticals, Inc. shares rose on early data from obesity candidates ARO-INHBE and ARO-ALK7, but I have more questions than answers. INHBE-targeted monotherapy is unlikely to drive meanin
Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.
11:26am, Tuesday, 06'th Jan 2026
Arrowhead's experimental therapy helped patients on Lilly's Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials
10:32am, Tuesday, 06'th Jan 2026
Arrowhead, Inc. (NASDAQ: ARWR) on Tuesday shared interim results from two Phase 1/2a trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics for obesity.
Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss
07:30am, Tuesday, 06'th Jan 2026
Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™ (plozasir
Mauro Ferrari Sells 7,530 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock
05:54am, Thursday, 01'st Jan 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) Director Mauro Ferrari sold 7,530 shares of the stock in a transaction that occurred on Friday, December 26th. The stock was sold at an
HBK Sorce Advisory LLC Invests $2.82 Million in Arrowhead Pharmaceuticals, Inc. $ARWR
05:35am, Monday, 29'th Dec 2025
HBK Sorce Advisory LLC acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm
Christopher Richard Anzalone Sells 13,445 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock
04:44am, Thursday, 25'th Dec 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 13,445 shares of the business's stock in a transaction on Friday, December 19th. The stock was so
Christopher Richard Anzalone Sells 12,586 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock
04:44am, Thursday, 25'th Dec 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 12,586 shares of the firm's stock in a transaction dated Monday, December 22nd. The shares were s
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
07:30am, Tuesday, 23'rd Dec 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar �
Christopher Richard Anzalone Sells 85,000 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock
04:02am, Sunday, 21'st Dec 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 85,000 shares of the business's stock in a transaction dated Wednesday, December 17th. The stock
Arrowhead Pharmaceuticals, Inc. $ARWR Holdings Boosted by Assenagon Asset Management S.A.
03:25am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. raised its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 1,388.6% during the undefined quarter, according to the company in its most recent 13
